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Background: Branched-chain amino acids, especially leucine, are known to interact with insulin signaling pathway
and glucose metabolism. However, the mechanism by which this is exerted, remain to be clearly defined. In order
to examine the effect of leucine on muscle insulin signaling, a set of experiments was carried out to quantitate
phosphorylation events along the insulin signaling pathway in human skeletal muscle cell cultures. Cells were
exposed to insulin, leucine or both, and phosphorylation events of key insulin signaling molecules were tracked
over time so as to monitor time-related responses that characterize the signaling events and could be missed by a
single sampling strategy limited to pre/post stimulus events.
Results: Leucine is shown to increase the magnitude of insulin-dependent phosphorylation of protein kinase B
(AKT) at Ser473 and glycogen synthase kinase (GSK3β) at Ser21-9. Glycogen synthesis follows the same pattern of
GSK3β, with a significant increase at 100 μM leucine plus insulin stimulus. Moreover, data do not show any
statistically significant increase of pGSK3β and glycogen synthesis at higher leucine concentrations. Leucine is also
shown to increase the magnitude of insulin-mediated extracellularly regulated kinase (ERK) phosphorylation;
however, differently from AKT and GSK3β, ERK shows a transient behavior, with an early peak response, followed by
a return to the baseline condition.
Conclusions: These experiments demonstrate a complementary effect of leucine on insulin signaling in a human
skeletal muscle cell culture, promoting insulin-activated GSK3β phosphorylation and glycogen synthesis.Background
Insulin signaling pathway [1] is characterized by cascades
of phosphorylation events, which activate and deactivate
molecules critical for physiological responses such as glu-
cose uptake, protein synthesis, and glycogen production
(Figure 1). In particular, insulin interacts with the insulin
receptor and modulates its signaling through phosphoryl-
ation of insulin receptor substrate 1 (IRS1) or its homo-
log IRS2. The C-terminal tail of IRS1 and IRS2, which
contains several tyrosine and serine phosphorylation
sites, binds the enzyme phosphoinositide 3-kinase (PI3K).
PI3K converts PI(4,5)P2, a membrane inositol phospho-
lipid, into PI(3,4,5)P3, which recruits 3-phosphoinositide-* Correspondence: toffolo@dei.unipd.it
1Department of Information Engineering, University of Padua, Padua, Italy
Full list of author information is available at the end of the article
© 2014 Di Camillo et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumdependent protein kinase-1 (PDK1) to the plasma mem-
brane, where PDK1 activates protein kinase B (AKT).
AKT phosphorylates many substrates important for cell
survival, regulation of growth and glycogen synthesis, gene
expression, and glucose uptake. In particular, AKT acts on
glycogen synthase kinase GSK3β by phosphorylating and
thus inactivating it and, in turn, activating the enzyme
glycogen synthase which is responsible for adding UDP-
glucose to a growing chain of glycogen. AKT also acts
on the mammalian target of rapamycin (mTOR), a multi-
domain Serine/Threonine kinase that phosphorylates
eukaryotic initiation factor 4E binding protein 1 (4EBP1),
which inactivates eIF4E, allowing initiation of transla-
tion. In addition to 4EBP1, mTOR also regulates S6 kin-
ase (S6K), which, besides leading to an increase in protein
synthesis and cell proliferation, exerts a feedback effecttral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
Figure 1 Insulin signaling pathway. The scheme represents the
current knowledge on insulin signaling downstream of the
insulin receptor (IR). Proteins that were measured by our
experiment are circled and marked with the corresponding
phosphorylation sites.
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rhabdomyosarcoma 1 (FOXO1). The specific function of
this transcription factor has not yet been well determined;
however, it is known to act as a regulator of cell response
to oxidative stress and may play a role in myogenic growth
and differentiation.
Notably, the insulin signaling network involves at least
another major pathway, the extracellularly regulated
kinase (ERK) - mitogen activated protein kinase (MAPK).
The ERK-MAPK pathway can be considered as a general
signaling pathway that is activated by a number of growth
factors, including insulin itself, all leading to enhanced cell
growth. Insulin triggers the ERK-MAPK pathway upon
binding of Grb2 (growth factor receptor binding protein
2) to Tyr-phosphorylated Shc or IRS proteins via its SH2
(Src-homology-2) domain. The signal is then propagated
to ERK1 and ERK2, which are translocated to the nucleus
where they activate cell proliferation.
Branched-chain amino acids (BCAAs), especially leu-
cine, are known to interact with insulin signaling path-
way. In particular, leucine is an essential amino acid,
which has been shown to promote protein synthesis
[2,3]; however, the mechanism by which this is exerted is
still controversial and seems to depend on cell type. An
increase of the phosphorylation state of mTOR and its
downstream regulators of protein synthesis S6K and
4EBP1 has been observed in mouse and rat muscle cells
treated with leucine plus insulin [4,5]. On the opposite,
in Zeanandin et al. [6], mTOR/S6K signaling pathway
was not significantly altered in muscle of rats subjected
to long-term dietary leucine excess, whereas it was in-
creased in rat adipose tissue.Leucine was also reported to exert inhibition on the
early steps of insulin signaling leading to insulin resist-
ance in rats after 5 weeks of dietary leucine supplemen-
tation [7]. Moreover, leucine deprivation in human
HepG2 cells and mouse primary hepatocytes has been
shown to improve hepatic insulin sensitivity by decreas-
ing mammalian target of rapamycin/S6K1 signaling [8].
In contrast with the above findings, a high-protein diet
was found to lower postprandial blood glucose in per-
sons with type 2 diabetes and improve overall glucose
control [9]. Along this line, Macotela et al. have recently
reported, using rodent models, that doubling dietary leu-
cine for eight weeks can reverse many of the metabolic
abnormalities associated with high fat diet-induced obes-
ity, improving glucose tolerance [10].
Since many events secondary to leucine administration
can occur during in vivo studies, but not during in vitro
experiments, there is still quite a bit of uncertainty on
the precise role of leucine in regulating glucose metabol-
ism. Perhaps leucine also acts at multiple points along
the insulin signaling pathway and its overall effect may
be the combination of its multiple effects; thus, examin-
ing the effects of leucine on mTOR targets as well as
classical insulin signaling molecules such as AKT and
ERK may be relevant for elucidating its effects.
The aim of the current study is to examine the effect
of leucine on insulin signaling cascade in a human skel-
etal muscle cell line. To accomplish this goal it is crucial
to track phosphorylation events over time so to monitor
time-related changes of signaling events. This also allows
monitoring transient changes in phosphorylation of sig-
naling proteins, which may be missed when sample col-
lection is limited to pre and post stimulus events. The
only practical way to monitor dynamic response is to
use a cell line, because it is not possible to perform mul-
tiple, rapid sampling experiments in animals. Moreover,
an in vitro study offers the opportunity to assess the dir-
ect effect of leucine rather than the effects that occur
through secondary events.
A skeletal muscle cell line was chosen to this purpose,
because this tissue plays a key role in whole body glu-
cose metabolism, by accounting for 70-80% of insulin-
mediated glucose uptake in healthy humans [11,12]. Cell
lines were exposed to insulin, leucine and leucine + insu-
lin stimulus and total and phosphorylated AKT, ERK1/2,
GSK3β, FOXO1, mTOR, 4EBP1, P70S6K were measured
using Western blots at 6 time points collected in the
60 minutes following stimulation. In particular, to iden-
tify proteins whose phosphorylated/total ratio changes
in time, we applied a statistical test specifically de-
signed to select differentially expressed proteins based
on their overall dynamic profile monitored during a
perturbation. Glycogen synthesis at 90 minutes was also
monitored in the three experimental conditions and at
Di Camillo et al. BMC Cell Biology 2014, 15:9 Page 3 of 9
http://www.biomedcentral.com/1471-2121/15/9four different leucine concentrations in the leucine +
insulin experiment.
Results
Muscle cells were deprived of serum overnight prior to
exposure to three different stimuli: A) cells were stimu-
lated with insulin at time 0′; B) cells were stimulated
with leucine at time 0′; C) cells were pre-incubated with
leucine for one hour and then stimulated with insulin
(Figure 2). Cells were exposed to stimuli for the follow-
ing durations: 0′, 2′, 5′, 10′, 30′, and 60′ and AKT,
pAKT-S473, ERK1/2, ppERK1/2-T202-Y204, GSK3β,
ppGSK3β-S21-S9, FOXO1a, pFOXO1-S256, mTOR,
pmTOR-S2448, 4EBP1, pp4EBP1-T37-T46, P70S6K, and
pP70S6K-T389 were measured using Western blots.
Each experiment was repeated three times including cell
cultures, so to have three available biological replicates.
It is important to note that leucine does not alter insu-
lin level, since average insulin concentration across the
three experimental replicates is equal to 88 ± 13 nM when
only the insulin stimulus is applied, and remains simi-
lar, i.e. equal to 87 ± 6 nM, when leucine is added to the
medium (data expressed as mean ± standard deviation).
The average dynamic response of proteins treated with
insulin, leucine and leucine + insulin is depicted in Figure 3.
As explained in section Methods, data are expressed
relative to the baseline band to correct for the antibody
efficiency. Moreover, to allow for comparison among dif-
ferent membranes, the ratios between phosphorylated and
total proteins is calculated. Figure 3 also shows standard
deviations calculated across the three biological replicates
and the results of the t-tests performed on single timeFigure 2 Experimental setup. Three experimental conditions:
A) Stimulation with insulin at time 0′ (ins); B) Stimulation with
leucine at time 0′ (leu); C) 60 minutes pre-incubation with leucine
followed by stimulation with insulin at time 0′ (leu + ins).point for each treatment vs. the baseline (stars indicate
p-values lower than 0.05) and on single time point for in-
sulin vs. leucine + insulin treatment comparisons (triangles
indicate p-values lower than 0.05).
In addition to that, the “Bounded Area” method, ori-
ginally described in [13], was applied to the time courses
of the ratio between phosphorylated and total proteins
monitored in a single replicate, to identify, for each pro-
tein, the replicates whose overall dynamic profile is sig-
nificantly modulated by insulin, leucine and/or leucine +
insulin treatment. The results are summarized in Table 1,
in terms of False Discovery Rate corrected p-value (empty
cells indicate that data were not available). For FOXO1
and P70S6K, for example, results refer to one repli-
cate only, since in two replicates the phosphorylated
protein concentration at time t = 0′ was below the de-
tection threshold, thus making impossible to perform
the normalization step to correct for antibody effi-
ciency (see section Methods).
According to our results, leucine alone has virtually no
effect on monitored phosphorylation events, since varia-
tions with respect to baseline are never significant when
performing a t-test on single time-points across the
three replicates (Figure 3, black bars) and are significant
only for one replicate of mTOR when the Bounded Area
method is applied to consider the overall dynamic pro-
file of each protein (Table 1).
Insulin alone has a major upregulatory effect on AKT,
ERK and GSK3β (Figure 3, red bars indicating average
measurements under insulin stimulus with red stars in-
dicating statistical significance with respect to the base-
line). In particular, pAKT/AKT shows an immediate
significant rise at time 2′, which is maintained in the fol-
lowing 60′, whereas pERK/ERK and pGSK3β/GSK3β
return to the baseline after an early rise. Considered on
the overall dynamic profile of each protein (Table 1), in-
sulin effect is significant in all biological replicates for
AKT and GSK3β, and in two out of three replicates for
ERK. Addition of leucine potentiates the insulin effect
on phosphorylation (Figure 3, blue bars) since pAKT/
AKT, pERK/ERK and pGSK3β/GSK3β are significantly
higher than baseline at all sampling times (Figure 3, blu
stars), and are significantly higher than with insulin
alone at most sampling times (Figure 3, black triangles).
In terms of overall time-series effect (Table 1), pAKT/
AKT, pERK/ERK and pGSK3β/GSK3β are all upregu-
lated in all biological replicates with leucine + insulin
both with respect to baseline and in comparison with in-
sulin alone.
The pattern of pmTOR/mTOR, which is responsible
for 4EBP1 and p70S6K phosphorylation, is more difficult
to be deciphered given the high variability among the
three replicates. Single time point comparisons (Figure 3)
do not allow to detect any significant difference after
Figure 3 Effects of insulin, leucine and leucine + insulin treatments on proteins’ phosphorylation. Time-series expression profiles showing
average and standard deviation of the data normalized to their time 0′ value and expressed as phosphorylated/total ratios under insulin (red),
leucine (black) and leucine + insulin (blue) stimulus. Stars indicate significant p-values of t-tests performed on single time point for each treatment
vs. the baseline. Triangles indicate significant p-values of t-tests performed on single time point for insulin vs. leucine + insulin treatment.
Representative Western blots of total and phosphorylated AKT, GSK3β and ERK proteins are shown in the lowest right panel.
Table 1 Results of the bounded area test
Treatment INS LEU LEU + INS LEU + INS vs. INS
Biological replicate R1 R2 R3 R1 R2 R3 R1 R2 R3 R1 R2 R3
pAKT/AKT 7e−3 7e−5 4e−3 >0.5 >0.5 >0.5 3e−5 1e−5 2e−5 2e−2 1e−5 4e−6
pGSK3β/GSK3β 3e−6 2e−2 4e−2 >0.5 >0.5 >0.5 3e−4 9e−4 2e−2 3e−2 8e−4 1e−3
pmTOR/mTOR >0.5 >0.5 >0.5 >0.5 3e−2 >0.5 >0.5 1e−2 2e−4 >0.5 >0.5 >0.5
pERK/ERK >0.5 9e−3 4e−2 >0.5 >0.5 >0.5 2e−2 4e−2 2e−2 2e−2 4e−2 2e−2
pp70S6K/p70S6K 4e−2 3e−2 8e−5
p4EBP1/4EBP1 >0.5 >0.5 >0.5 >0.5 >0.5 >0.5 6e−4 2e−2 2e−2 >0.5 >0.5 >0.5
pFOXO1/FOXO1 >0.5 >0.5 1e−2 >0.5
Results of the Bounded Area method [13], applied to the time courses of the ratio between phosphorylated and total proteins monitored in a single replicate, to
identify, for each protein, the replicates whose overall dynamic profile is significantly modulated by insulin, leucine and/or leucine + insulin treatment. False
Discovery Rate corrected p-values are reported. Empty cells indicate that data are not available.
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leucine, whereas the overall profile (Table 1) is not sig-
nificantly expressed in any replicate during insulin
stimulus, but indicates up-regulation in two out of three
replicates under leucine + insulin stimulus.
p4EBP1/4EBP1 appears to be significantly up-regulated
only at time 5′ and 10′ following leucine + insulin stimu-
lus (Figure 3), but this is sufficient to elicit a significant
overall effect of leucine + insulin in all replicates (Table 1),
when compared to baseline.
As regards FOXO1, which is a target of AKT, data
shown in Figure 3 suggest some effect under leucine +
insulin stimulus, but since just one replicate is available,
it is not possible to derive any statistical conclusion. Ap-
plication of the Bounded Area method to this single rep-
licate, however, confirms an up-phosphorylation under
leucine + insulin stimulus.
Even for pp70S6K/p70S6K only one replicate is avail-
able. The time course data (Figure 3) suggest a 2-fold up-
regulation by insulin, potentiated by leucine to 18-fold
up-regulation. The overall effect on the available repli-
cates is significant with insulin as well as with leucine +
insulin and is still significant when comparing leucine +
insulin vs. insulin stimulus.
Results from the experiment carried out to measure
glycogen synthesis are shown in Figure 4: leucine alone
has no effect on glycogen synthesis, whereas both insulin
and leucine + insulin conditions resulted in a significant
increase with respect to the baseline (p-value = 0.0157
and 0.006, respectively), and the difference between the
two conditions is statistically significant (p value =0.008).
This finding is consistent with the observation that GSK3β
phosphorylation was not altered by leucine and was in-
creased instead both with insulin and leucine + insulin
stimuli, given that GSK3β has an inhibitory role on glyco-































Figure 4 Effects of insulin and leucine on glycogen synthesis. Average
(no stimulation) in the three biological replicates. Error bars denote sta
with a star (*).As regards the effect of increasing leucine concentration
on GSK3β and glycogen synthesis, it appears that 100 μM
leucine concentration is able to elicit an elevated re-
sponse, not far from those observed with 200-300-400 μM
for both phosphorylated GSK3β (Figure 5, panel A) and
glycogen synthesis (Figure 5, panel B). Even if data may
suggest that the maximum effect is not reached with
100 μM, the low number of replicates do not allow to as-
sess any statistically significant difference of pGSK3β and
glycogen synthesis at higher concentrations.
Discussion
The main finding of this work is that leucine modulates
the phosphorylation of insulin signaling proteins in a
way that is specific for each studied target, suggesting a
coordinated regulation of insulin and leucine on insulin
signaling. In particular, leucine is shown to increase the
magnitude of insulin-mediated AKT phosphorylation at
Ser473, which remained moderately elevated through
60 minutes with insulin, highly elevated with leucine +
insulin, not altered with leucine alone. GSK3β, which is
known to be phosphorylated by AKT, shows a similar
pattern of activation. 100 μM of leucine are sufficient to
increase the effect of insulin on GSK3β phosphorylation,
which did not appear to be further upregulated at a sig-
nificant extent if the concentration of leucine is in-
creased above this value, although a positive trend can
be observed from the data. Consistently, glycogen syn-
thesis followed the same pattern of GSK3β, with leucine
increasing the insulin-mediated glycogen synthesis by
50% (p-value 0.008). Leucine was also shown to increase
the magnitude of insulin-mediated ERK phosphorylation;
however, differently from pAKT and pGSK3β when
treated by leucine + insulin, pERK shows a transient be-
havior, with a peak at 10′ followed by a return to the
baseline condition. This behavior has already been re-
ported in the literature under insulin stimulus and underleu leu+ins
*
newly synthesized glycogen expressed relative to the baseline



























































Figure 5 Dose effect of leucine on GSK3β and glycogen synthesis. Panel A: amount of GSK3β total (green) and phosphorylated (pink).
Panel B: glycogen synthesis with varying concentrations of leucine.
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ERK response might be obtained by a feedback of SOS,
the son of sevenless homolog protein, which prevents a
sustained activation of ERK that would result in contin-
ual cell proliferation [14].
mTOR, which is expected to be an additional target of
leucine, showed partial inconsistency among different
replicates. Lack of a clear effect by leucine at this site
may suggest that leucine activates mTOR in human skel-
etal muscle by involving additional phosphorylation sites.
The site investigated here is known to be phosphorylated
by AKT; nonetheless, in a recent work [15], it was dem-
onstrated that mTOR signaling complex 1 (mTORC1),
which regulates p70S6K, contains mTOR phosphory-
lated predominantly on S2448 (the site monitored here),
whereas mTOR signaling complex 2 (mTORC2), which
regulates Akt through S473 phosphorylation, contains
mTOR phosphorylated predominantly on S2481. This
observation suggests to monitor in future studies mTOR
complex formation rather than the targeted phosphoryl-
ation site used here.
In this experiment, only one replicate is available for
phosphorylated p706SK at T389 site. pp706SK resulted
to be 2-fold up-regulated under insulin and 18-fold up-
regulated under leucine + insulin stimulus with a peak at10′, and showed a significant effect of leucine when in-
cubated before insulin stimulus. Our results are in agree-
ment with [16], in which healthy adults were infused
with leucine alone, insulin alone, or both leucine and in-
sulin for 2 hours, and p70S6k and AKT phosphorylation
were measured in vastus lateralis muscles showing up-
regulation under leucine + insulin stimulus. Analogously,
in [17], phosphorylation of mTOR and p70S6K was tran-
siently increased in human myotubes following leucine,
insulin and leucine + insulin treatment. While results in
[16,17] suggest that leucine and insulin act in an additive
manner to increase p70S6k phosphorylation, other studies
on skeletal muscle in pigs using an amino acid/insulin
clamp [18], do not evidence any effect of amino acids on
insulin induced stimulation of either IRS1 or Akt phos-
phorylation. As pointed out in the Introduction, in
different studies a downregulation of leucine on insu-
lin signaling was reported [7,8]; in particular, in [8]
leucine deprivation in human HepG2 cells and mouse
primary hepatocytes has been shown to improve hep-
atic insulin sensitivity by decreasing mammalian tar-
get of rapamycin/S6K1 signaling [8]. There might be
different possible reasons of these controversial results in
the literature among studies targeting leucine effect on
insulin signaling. First, literature studies differ for being
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volving different tissues and pathways can interact in
an integrated fashion. Second, different studies are
applied to different cell lines and tissues, in human
or animal models. Third, experimental conditions are often
different, being e.g. characterized by different amino acids
and nutrient availability and/or different leucine incuba-
tion times/doses. For example, the deprivation of all
amino acids in our experiment is likely to cause protein
synthesis repression. Accordingly to [8], this leads to the
activation of GCN2 and repression of p706SK, which was
evident in our data since pp706SK at time 0′ was not de-
tectable in our study in two out of three replicates. In our
study, however, differently from [8], when cells are stimu-
lated with leucine, the signaling system seems to respond
to insulin in an enhanced way. It must be pointed out here
that in our study muscle cells are in a state of amino acids
deprivation and leucine availability, whereas in [8] cells,
which are hepatic cells, are cultured with all amino acids
but leucine. In this regards, since a wide range of signals,
including nutrients, energy levels, growth factors, and
amino acids are known to affect insulin signaling pathway,
it is likely that experimental results strongly depend on
the availability of combinations of the above variables.
Moreover, the proteins involved in the insulin signaling
pathway are known to exhibit a number of different phos-
phorylation sites, able to interact in different ways with
different molecules, a complex set of regulatory mecha-
nisms which are not completely understood, as for ex-
ample in the case of mTOR [15]. Another reason of the
discrepancies observed in the literature regarding leucine
effect on insulin signaling pathway is that in most studies
a single time point is measured and, as made evident by
Figure 3, this can lead to different conclusions.
In summary, well controlled and standardized proto-
cols, together with methods for monitoring phosphoryl-
ation events in a more high-throughput fashion, in
experiments addressing the combined dynamic effect of
insulin, leucine and other amino acids, in a variety of tis-
sues and cell types, are needed by the scientific commu-
nity to better clarify the complex regulatory pathway of
insulin signaling system.
The present work, although not conclusive in terms of
possible effects of leucine in insulin signaling pathway,
demonstrates the importance of tracking phosphoryl-
ation events in time and with a proper sampling grid.
Since phosphorylation events are likely to be transient,
testing a single time point can lead to false negative find-
ings due to lack of detection, even though phosphoryl-
ation occurs. Of note, these experiments only report on
skeletal muscle cell lines. Although by using cell lines the
environment studied cannot reproduce all of the complex-
ities that occur in vivo, an advantage is that cell culture
models are particularly suited to studying phosphorylationtransient events because the timing of events can be stud-
ied with precision. It would be helpful to follow up with
similar studies on human hepatic cell lines to determine
whether a similar trend is observed in another cell type
that is important for glucose metabolism.
Conclusions
In order to examine the effect of leucine, an essential
branched-chain amino acid, on muscle insulin signaling,
a set of experiments was carried out to quantitate phos-
phorylation events along the insulin signaling pathway
in human skeletal muscle cell cultures. Cells were serum
starved overnight and exposed to insulin, leucine, or
both, and phosphorylation events of key insulin signaling
molecules were tracked over time so as to monitor time-
related responses that characterize the signaling events
and could be missed by a single sampling strategy lim-
ited to pre/post stimulus events.
Data show that leucine alone has no effect on AKT and
GSK3β phosphorylation; however, leucine preincubation
enhances the effect of insulin, amplifying the phosphoryl-
ation of AKT and GSK3β. This suggests that leucine does
not directly promote AKT and GSK3β phosphorylation,
but affects other signaling molecules that in turn, regulate
AKT and GSK3β. The increase in GSK3β phosphorylation
is then shown to lead to improved glycogen synthesis, be-
ing of potential interest for insulin-resistant states.
Leucine is also shown to increase the magnitude of
insulin-mediated ERK phosphorylation; however, differ-
ently from AKT and GSK3β, ERK shows a transient be-
havior, with an early peak response, followed by a return
to the baseline condition.
Methods
Experimental design
Muscle cells were deprived of serum overnight prior to
exposure to three different stimuli: A) cells were stimu-
lated with insulin at time 0′; B) cells were stimulated
with leucine at time 0′; C) cells were pre-incubated with
leucine for one hour and then stimulated with insulin
(Figure 2). Cells were exposed to stimuli for the following
durations: 0′, 2′, 5′, 10′, 30′, and 60′ and AKT, pAKT-
S473, ERK1/2, ppERK1/2-T202-Y204, GSK3β, ppGSK3β-
S21-S9, FOXO1a, pFOXO1-S256, mTOR, pmTOR-S2448,
4EBP1, pp4EBP1-T37-T46, P70S6K, and pP70S6K-T389
were measured using Western blots. Each experiment
was repeated three times including cell cultures, so to
have three available biological replicates. Measurements
of each biological replicate were repeated in a number of
technical replicates ranging from 2 to 5, performed on dif-
ferent blots. Glycogen synthesis at 90 minutes was also
monitored in the three experimental conditions. All the
experiments were repeated three times, thus three bio-
logical replicates were available for each condition.
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lus was run with four different concentration of leucine:
100, 200, 300 and 400 μM; glycogen synthesis and ppGSK3α/
β-S21-S9 at 90 minutes were monitored at these different
concentrations.
Cell cultures
Human skeletal muscle cells (SkMCs) and growth medium
(SkGM) were purchased from Lonza. Cells were prolifer-
ated on 6-well plates between 5 and 7 passages at 37°C,
5% CO2, grown to 90% confluence and exposed to differ-
entiation medium (DMEM:F12 w/2% Horse Serum and
gentamycin) for ten days. Glucose was not added to the
medium, but was present in the DMEM at 1000 mg/L.
Cells were serum-starved with DMEM O/N and then
switched to Earle’s Balanced Salt Solution (EBSS) for
one hour, after which they were exposed to one of three
media: 1) EBSS + 100 nM insulin, 2) EBSS + 400 μM leu-
cine, or 3) EBSS + 400 μM leucine (1H priming) followed
by EBSS + 100 nM insulin + 400 μM leucine. The 100 nM
concentration represents a well-accepted level of insulin
stimulation in cell cultures commonly found in the litera-
ture [8].
Immunoblotting
Cells were lysed with Cell Signaling lysis buffer, sonicated,
and centrifuged at 14KG for 30 minutes at 4°C. Cell Sig-
naling Lysis buffer was composed by 20 mM Tris–HCl
(pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA,
1% Triton, 2.5 mM sodium pyrophosphate, 1 mM b-
glycerophosphate, 1 mM Na3VO4, 1 μg/ml leupeptin, We
also added Halt Protease and Phosphatase inhibitor cock-
tail. The Pierce 660 reagent was used to determine protein
concentrations and lysates were loaded onto Invitrogen
Nupage gels for Western blot transfer using the Biorad
semi-dry Trans-blot apparatus. Blots were blocked with
Licor blocking buffer and incubated overnight at 4°C
with target antibodies. Cell Signaling supplied all pri-
mary antibodies with the exception of FOXO1a and
GSK3β antibodies, which were from Abcam. In details,
the antibodies used were: Akt total – Cell Signaling #2920;
Akt Phospho (Ser473) – Cell Signaling #9271; GSK-3B
total – Abcam #ab2602; GSK-3B-phospho (Ser9) – Cell
Signaling #9336; ERK1/2 total – Cell Signaling #4695;
ppERK1/2 (T202-Y204) – Cell Signaling #9106; FOXO1a
total – Abcam # ab89433; pFOXO1a (S256) – Cell Sig-
naling #9461; mTOR – Cell Signaling #2983; pmTOR
(S2448) – Cell Signaling #2971; 4EBP1 – Cell Signaling
#9644; pp4EBP1 (T37-T46) – Cell Signaling #9459; P70S6K
– Cell Signaling #9202; pP70S6K (T389) – Cell Signaling
#9206. All were used at a 1:1000 concentration.
Band densities were quantified using the Licor Odyssey
system using the integrated intensity value for each band.
In the case protein concentration at time 0′ was difficultto detect because too low, it was necessary to concentrate
lysates before loading them onto gels, using Vivaspin
MWCO 30 kDa concentrating filters.
To allow for comparison between the total and the
phosphorylated fraction of each protein, the time 0′
baseline sample was loaded on every gel and all other
band densities were expressed relative to the baseline
band to correct for the antibody efficiency. Moreover, to
allow for comparison among different membranes, the
ratios between phosphorylated and total proteins were
calculated. Since for each protein, the total and the
phosphorylated fractions were loaded in the same lane,
this latter step also corrected for possible differences in
the quantity of sample loaded in each gel. Therefore
Beta-actin, which was also measured in each lane and is
reasonably stable across the different lanes and blots,
with mean equal to 16 and standard deviation equal to
3, was not used to normalize the data. Finally, technical
replicates were averaged.
Glycogen synthesis assay
Priming media were removed and media containing uni-
formly labelled 14C-glucose were added to the cultures.
After 90 minutes, medium was removed, cells were
washed with PBS and extracted with 1 ml 0.03% SDS
(0.15 ml used for protein determination and 0.85 ml for
glycogen extraction). Carrier glycogen was added, sam-
ples were heated to 95°C for 30 minutes and glycogen
pellets were collected by centrifugation, washed with
70% ethanol, and resuspended in 200 μl distilled water.
The incorporation of 14C-labeled glucose into glycogen
was determined by 15 minute counts in a beta counter,
using 10 ml optifluor liquid scintillation cocktail per
sample. The stock 14C-glucose had a specific radioactivity
of 7400 kBq/ml. The concentration used in the glycogen
synthesis assay was 18 kBq/ml. Media was made using
31.63ul of the stock 14C-glucose into a total volume of
13 ml of media. Glycogen synthesis was expressed relative
to its baseline. Each condition was run at least in triplicate.
Statistical methods
The Standard t-test was applied to assess if, for each time
point, the ratio between phosphorylated and total protein
was significantly different from 1, i.e. the baseline value at
time t = 0, or if there were differences between different
treatments. P-value < 0.05 was considered significant.
In addition to that, the “Bounded Area” method, ori-
ginally described in [13], was applied to the time courses
of the single replicates, to identify, for each protein, the
replicates whose overall profile is significantly modu-
lated by insulin, leucine and/or leucine + insulin treat-
ment. Briefly, the area bounded by the protein profile
with respect to its baseline value was evaluated, and
the protein was considered differentially expressed if
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threshold determined in correspondence to a significance
level α, based on the null hypothesis distribution. This lat-
ter was derived by repeatedly sampling data from an error
distribution, empirically obtained from the available bio-
logical replicates as explained in [19]. As already shown,
the method is quite robust to random oscillation since the
entire expression profile is considered, thus diminishing
both false positive and false negative rates with respect to
standard tests when few replicates are available. Moreover,
both the precision and the recall of the test are en-
hanced by the fact that the entire expression profile
is tested, rather than single time points [13,20]. In
order to account for multiple testing, the significance
level α was corrected for multiple testing so to con-
trol the global False Discovery Rate at 5% [21]. The
analysis was applied separately for the three available
biological replicates, thus allowing to check for consistency
of different experiments. The “Bounded Area” method
was applied also to test differences between different
treatments.
Differences in glycogen synthesis and GSK3β measured
at different doses of leucine incubation followed by in-
sulin stimulus were assessed using standard ANOVA
and t-tests. P-value < 0.05 was considered significant.
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